Additional Information

This program was based on a multidisciplinary conference of leaders in bladder cancer research and clinical care. The focus of the program was to convene a meeting of 10 nationally recognized multidisciplinary leaders in bladder cancer research and treatment to share recent data, identify significant gaps in current knowledge and develop recommendations for advancing the field, and communicate this information to the larger medical community focusing specifically on neoadjuvant chemotherapy in invasive disease and treatment of high-risk superficial disease

This program was directed by Colin P. N. Dinney, MD, Professor and Chairman, Department of Urology, Professor, Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas and Maha Hussain, MD, FACP, Professor of Medicine & Urology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

The consensus summary paper “Bladder Cancer: Narrowing the Gap Between Evidence and Practice” was publised in Journal of Clinical Oncology December 2009 Vol 27, No 34: pp. 5680-5684.

A link for an online monograph that was produced is listed below. 

Educational Need
Physicians who manage and counsel patients with bladder cancer need to assess and integrate into their practice of treatment and patient counseling: (a) the current framework for assessing appropriate use of systemic chemotherapy for muscle-invasive disease and (b) optimal approaches to treating superficial bladder, particularly for BCG-resistant disease. 

Educational Grant Support
Supported by educational grants provided by Bristol-Myers Squibb Company, Eli Lilly and Company and Schering Corporation.

Sponsorship
CME sponsorship was provided by InforMEDical Communications, Inc.